Results 221 to 230 of about 4,495,861 (247)

Engineered Nanoplatforms Targeting Activated Hepatic Stellate Cells for Liver Fibrosis Therapy via TGF‐β Axis Inhibition and Ferroptosis Induction

Advanced Healthcare Materials, EarlyView.
FeS‐VA@lanifibranor (FVL), an activated hepatic stellate cell (aHSC)‐targeted nanoplatform comprising vitamin A‐functionalized two‐dimensional iron sulfide nanosheets and lanifibranor, is engineered for precision therapy of liver fibrosis. FVL suppresses the TGF‐β signaling pathway by inhibiting SMAD2/3 phosphorylation and induces ferroptosis in aHSCs,
Yinuo Yang, Mengyao Mu, Ke Ren, Hui Liu, Pengju Ma, Yingqi Wang, Mengmeng Zhang, Xueli Xu, Wenzhe Li, Wenshuang Gao, Xiao Sun, Qiang Zhu   +11 more
wiley   +1 more source

Safety profile of ticagrelor: an analysis based on literature and database review. [PDF]

BMC Cardiovasc Disord
Liu R, Xiao L, Yan Q, Liu X.
europepmc   +1 more source

Safety profile and potential clinical risks of xanomeline and trospium chloride: A real-world pharmacovigilance study using FAERS. [PDF]

Neurotherapeutics
Bao Z, Liu Y, Liu Y.
europepmc   +1 more source

Therapeutic potential of allicin against viral infections: Mechanisms and safety profile (Review). [PDF]

Exp Ther Med
Yu MJ, Zhu Y, Zhang W, Xu QP, Wang HM, Ma Z.   +5 more
europepmc   +1 more source

Real-world safety profile of givinostat: an early post-marketing pharmacovigilance study based on the FAERS database. [PDF]

Front Pharmacol
Xu J, Xiao C, Li L, Ma X, Xia S, Ji H, Shi F.   +6 more
europepmc   +1 more source

Safety profile following mRNA-1273 COVID-19 primary vaccination in healthy adults in Indonesia. [PDF]

Glob Epidemiol
Medise BE, Kaswandani N, Putri ND, Leonard E, Angkasa PF, Putra A, Muliasari R, Indriani V, Yosephine P, Sundoro J, Satari HI, Hadinegoro SR.   +11 more
europepmc   +1 more source